Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Artisan Partners Limited Partnership Invests $23.38 Million in Foley Trasimene Acquisition Corp. II (NYSE:BFT)
Artisan Partners Limited Partnership acquired a new position in shares of Foley Trasimene Acquisition Corp. II (NYSE:BFT) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,548,218 shares of the company’s stock, valued at approximately $23,378,000. Artisan Partners Limited Partnership owned 1.20% of Foley Trasimene Acquisition Corp. II as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. HighTower Advisors LLC bought a new stake in shares of Foley Trasimene Acquisition Corp. II in the fourth quarter valued at approximately $191,000. Advisory Services Network LLC bought a new stake in shares of Foley Trasimene Acquisition Corp. II in the fourth quarter worth $76,000. Full18 Capital LLC bought a new stake in shares of Foley Trasimene Acquisition Corp. II in the fourth quarter worth $2,442,000. Alliancebernstein L.P. bought a new stake in shares of Foley Trasimene Acquisition Corp. II in the fourth quarter worth $10,011,000. Finally, Sei Investments Co. bought a new stake in shares of Foley Trasimene Acquisition Corp. II in the fourth quarter worth $1,213,000.
https://zolmax.com/investing/artisan-partners-limited-partnership-invests-23-38-million-in-foley-trasimene-acquisition-corp-ii-nysebft/5541456.html
Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the following industry and investor conferences in March:
March 8-9: 2nd Annual European HealthTech CEO Forum. Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic, will participate in the "Advanced Therapeutics Panel" as part of the "Pandemic Response Day" on Tuesday, March 9, at 1:30 pm CET (7:30 am ET) to discuss the potential of IMU-838 as a treatment option for COVID-19.
March 9-10: H.C. Wainwright Global Life Sciences Conference. Dr. Vitt will present a company overview at the conference. The presentation will be available for viewing beginning March 9, at 7:00 am ET. An audio webcast of the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
March 11: BioCapital Europe 2021. Dr. Vitt will present a company overview on Thursday, March 11, at 10:50 am CET (4:50 am ET).
March 15-17: 33rd Annual Roth Conference. Dr. Vitt will participate in the "Therapies and Vaccines in the Fight Against COVID-19" panel on Monday, March 15, at 3:00 pm ET. In addition, Dr. Vitt will present a company overview. The presentation will be available for viewing anytime during the conference. Audio webcasts of both the panel discussion and the presentation will be available on the "Events and Presentations" section of Immunic's website at: ir.imux.com/events-and-presentations. An archived replay will be available on the company's website for a period of 90 days after the conference.
March 22-25: BIO-Europe Spring® Digital. Members of Immunic's management and business development teams will attend this conference and host one-on-one partnering meetings. To schedule a meeting, please use the BIO-Europe partnering portal at: https://informaconnect.com/bioeurope-spring/access-event/.
About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is developing three small molecule products: its lead development program, IMU-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect, is currently being developed as a treatment option for multiple sclerosis, ulcerative colitis, Crohn's disease, COVID-19, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor ROR?t, is targeted for development in psoriasis and Guillain-Barré syndrome. IMU-856, which targets the restoration of the intestinal barrier function, is targeted for development in diseases involving bowel barrier dysfunction. For further information, please visit: www.imux.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management's participation in industry and investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2020, filed with the SEC on February 26, 2021, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Contact Information
Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com
US IR Contact
Rx Communications Group
Paula Schwartz
+1 917 322 2216
immunic@rxir.com
US Media Contact
KOGS Communication
Edna Kaplan
+1 781 639 1910
kaplan@kogspr.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/immunic-inc-to-participate-in-industry-and-investor-conferences-in-march-301238220.html
SOURCE Immunic, Inc.
Get the Latest IMUX - Immunic, Inc. News & Updates!
IMUX Chart by TradingView
< Newer Post Older Post >
MARCH 04, 2021
Cowen 41st Annual Health Care Conference
https://ir.adctherapeutics.com/events-and-presentations/default.aspx
Not very encouraging: Corporate update March 2021
https://www.sec.gov/Archives/edgar/data/1553846/000117891321000845/zk2125665.htm
Once Covid is basically eradicated by the Summer, "ie.likely" the shareholders will of now paid for in-home case studies yet Covid could be just a bad memory for most.
I had originally bought into this company for its pipeline not as a Covid play, yet that is all the have really worked on for the last 10 months while no downsizing or upsized better sales coming from their over weighted salesforce.
I know that Q4 earnings will be out end of day, but if they even slightly beat, it is to little to late.
They have a line of credit, issued shares at a poorly offered price 8 weeks or so back and are doing another offering, upsized again. To much smoke and mirror's as this does not smell of institutional interest but H.C. Wainwright & Co. getting a sweet deal payday again.
I have never witnessed another offering like this one back to back and I supported the last one. And i`ll say, fool me once etc....
This is really unreal and is not going to go well for the company going forward as i`ve never seen a company being so vague and dilute again so soon without upfront communications whatsoever. I sold all holdings AH`s in this too evasive business that does not respect its shareholder base whatsoever.
They could of reorganized last year to save capital like downsizing the salesforce of the 150 that they keep, but no. They had a lot of options but they decided to further dilute again with the same sloppy pat reason.
Bought offering or not, the 25M offering should of been upsized more the last round. So this is all we get again, BS: "RedHill intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes."
10th Annual SVB Leerink Global Healthcare Conference
Give a listen if you one $IMUX
Thursday, February 25, 2021
https://wsw.com/webcast/svbleerink47/register.aspx?conf=svbleerink47&page=imux&url=https://wsw.com/webcast/svbleerink47/imux/2693120
IMUX Immunic shares a 'bargain' ahead of 'derisking catalysts,' says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target following the company's Q4 report. Immunic has "several derisking catalysts" during 2021, beginning with data in late March or early April from a new dose cohort of IMU-838 in relapsing-remitting multiple sclerosis to support a successful end-of-Phase 2 meeting and Phase 3 study start in the second half of the year, Jallah tells investors in a research note. Data from IMU-838, IMU-935 and IMU-856 "could support a higher valuation for a stock already trading at a bargain," says Jallah. The analyst believes current valuation levels offer a "nice entry point."
IMUX Piper remains 'bullish' on Immunic progress with IMU-838 after Q4 update
Piper Sandler analyst Yasmeen Rahimi said following Immunic's earnings release that she remains "bullish" on the company's continued progress in its EMPhASIS program for IMU-838 for relapsing-remitting multiple sclerosis, or RRMS, which she views "as a key value driver for the stock." The analyst, who also views the company's opportunity in ulcerative colitis with IMU-838 as "significantly underappreciated," keeps an Overweight rating and $71 price target on Immunic shares.
PAYSAFE LIMITED
Merger vote is March 25th @12pm
https://www.sec.gov/Archives/edgar/data/1833835/000119312521055290/d18419df4a.htm#toc
Foley-Alight Investor Conference Call for those that have not reviewed it yet or are new to this SPAC:
https://sec.report/Document/0001104659-21-007222/
Affimed (NASDAQ:AFMD) versus Spotlight Innovation (OTCMKTS:STLT) Critical Review
https://zolmax.com/investing/affimed-nasdaqafmd-versus-spotlight-innovation-otcmktsstlt-critical-review/5503524.html
Added to 2 accounts during this market sell off, lets see if it last as it seems to be turning back up after Powell's dovish comments help stocks off their lows.
Immunic updates make shares even more attractive, says Roth Capital
Roth Capital analyst Zegbeh Jallah keeps a Buy rating on Immunic with a $64 price target after the company presented detailed topline results from its Phase 2 CALVID-1 study of IMU-838 in hospitalized patients with moderate COVID-19 and new data for its Phase 2 investigator-sponsored study of IMU-838 in patients with primary sclerosing cholangitis. Both datasets are "supportive of continued development," Jallah tells investors in a research note. The analyst says that neither program is included in her model, creating "even more upside potential," in addition to a pipeline "that remains significantly undervalued."'
National Asset Management Inc. Acquires Shares of 18,825 Foley Trasimene Acquisition Corp. II (NYSE:BFT)
National Asset Management Inc. acquired a new stake in Foley Trasimene Acquisition Corp. II (NYSE:BFT) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 18,825 shares of the company’s stock, valued at approximately $285,000.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Focused Wealth Management Inc bought a new stake in Foley Trasimene Acquisition Corp. II in the 4th quarter valued at about $45,000. Black Swift Group LLC bought a new stake in Foley Trasimene Acquisition Corp. II in the 4th quarter valued at about $564,000. Creative Planning bought a new stake in Foley Trasimene Acquisition Corp. II in the 4th quarter valued at about $2,679,000. First Heartland Consultants Inc. bought a new stake in Foley Trasimene Acquisition Corp. II in the 4th quarter valued at about $237,000. Finally, Usca Ria LLC acquired a new position in shares of Foley Trasimene Acquisition Corp. II in the 4th quarter valued at approximately $2,584,000.
https://www.tickerreport.com/banking-finance/7090751/national-asset-management-inc-acquires-shares-of-18825-foley-trasimene-acquisition-corp-ii-nysebft.html
Your in good company:
AFFIMED INSTITUTIONAL BUYING AND SELLING
https://www.marketbeat.com/stocks/NASDAQ/AFMD/institutional-ownership/
Kinross Gold Corp. Becomes Oversold
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.
In trading on Friday, shares of Kinross Gold Corp. (TSE:K.CA) entered into oversold territory, hitting an RSI reading of 29.4, after changing hands as low as $8.31 per share. By comparison, the current RSI reading of the S&P/TSX Composite Index is 61.3. A bullish investor could look at K.CA's 29.4 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. The chart below shows the one year performance of K.CA shares:
Looking at the chart above, K.CA's low point in its 52 week range is $4 per share, with $13.59 as the 52 week high point — that compares with a last trade of $8.31.
http://www.canadastockchannel.com/article/202102/kinross-gold-corp-becomes-oversold-k-ca-K.CA02192021rsica.htm/
Getting some love of late:
HOOKIPA PHARMA (NASDAQ HOOK) INSTITUTIONAL BUYING AND SELLING
https://www.marketbeat.com/stocks/NASDAQ/HOOK/institutional-ownership/
Two fairly good PR`s the past couple of days and stock sells off 20% alone today. Bought some trading shares close to lows as the selling stopped at the 1 year 200 day SMA which sits at $16.12.
Also today Piper 'encouraged' by Immunic datasets for IMU-838
After Immunic filed "an in-depth 8K" with a detailed analysis of the Phase 2 CALVID-1 and Phase 2 PSC studies of IMU-838, Piper Sandler analyst Yasmeen Rahimi said she is "encouraged by both datasets," adding that the topline data from the Phase 2 proof-of-concept study for IMU-838 in 11 primary sclerosing cholangitis, or PSC, "strong." The analyst, who continues to see multiple sclerosis and ulcerative colitis as Immunic's "key value drivers," also said she views COVID-19 and PSC as "call optionalities." Rahimi keeps an Overweight rating and $71 price target on Immunic shares.
SNDL Stock and Forecast: Sundial Growers Inc falls on Friday, despite three reasons to rise
NASDAQ: SNDL has surged by 78.79% on Wednesday as retail traders have seized on it.
Sundial Growers Inc is benefitting from the better political climate toward marijuana.
Thursday's premarket trading is pointing to an additional 40% gain, also thanks to the first American IPO.
https://www.fxstreet.com/news/sndl-stock-and-forecast-sundial-growers-inc-skyrockets-for-three-reasons-and-why-it-could-go-higher-202102111155
Foley Trasimene Acquisition II Is a Surefire Fintech Winner
https://investorplace.com/2021/02/bft-stock-is-a-surefire-winner-in-the-online-payments-space/
Analyst Rating
Target Price Action Rating Action Analyst Rating Price Date
Target Raised by Barclays Overweight USD 9 » USD 10 2021-02-11
Initiated by JPMorgan Chase Overweight » Focus List 2021-02-10
Target Lowered by Stifel Nicolaus Buy USD 14.75 » USD 14.5 2021-02-08
Target Lowered by Raymond James Financial Outperform USD 14 » USD 13 2021-01-15
Reiterated by National Bank Financial Outperform 2021-01-11
Upgraded by Barclays Equal Weight » Overweight USD 9 2021-01-06
Target Set by Credit Suisse Neutral USD 10.5 2020-11-05
Maintains TD Securities Buy USD 15 » USD 15.5 2020-11-05
Target Raised by BMO Capital Markets Outperform USD 14.25 » USD 14.5 2020-10-21
https://www.stocktargetadvisor.com/stock/USA/NYE/KGC#analyst-rating-tab
Kinross Gold started at overweight just before earnings today with a $11 stock price target at J.P. Morgan on 2/10/2021.....
Point72 Asset Management, L.P. reports stake of 5.0%
One for the short crowd to take control. This is too many shorts for all Affimed has going:
Affimed (NASDAQ:AFMD) was the recipient of a significant increase in short interest in January. As of January 15th, there was short interest totalling 7,040,000 shares, an increase of 14.3% from the December 31st total of 6,160,000 shares. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 4.2 days.
Affimed stock opened at $5.74 on Friday. The stock has a market cap of $506.99 million, a PE ratio of -9.73 and a beta of 2.81. Affimed has a one year low of $1.42 and a one year high of $7.48. The stock has a fifty day moving average of $6.31 and a 200 day moving average of $4.60.
https://www.tickerreport.com/banking-finance/7035131/affimed-nasdaqafmd-short-interest-update.html
CERVICAL CANCER AWARENESS MONTH: AGENUS’ BREAKTHROUGH TREATMENTS AND TECHNOLOGIES FOR CERVICAL CANCER
https://agenusbio.com/newsletters/v4-i02_2021-cervical-cancer-awareness-month/
The Only Play On Agenus
https://seekingalpha.com/article/4401082-only-play-on-agenus
Redhill video today with chief business officer;
https://player.vimeo.com/video/501846217?autoplay=1
Should start picking up some decent coverage with all the company has going for it. Nice find......
A few days old but still relevant:
Sowell Financial Services LLC lifted its stake in shares of RedHill Biopharma Ltd. (NASDAQ:RDHL) by 4.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,574 shares of the biotechnology company’s stock after purchasing an additional 3,943 shares during the quarter. Sowell Financial Services LLC owned about 0.23% of RedHill Biopharma worth $708,000 at the end of the most recent quarter.
https://www.tickerreport.com/banking-finance/6943130/sowell-financial-services-llc-grows-stock-position-in-redhill-biopharma-ltd-nasdaqrdhl.html
Immunic: Competitive Phase 2 Data In Multiple Sclerosis
Jan. 24, 2021
https://seekingalpha.com/article/4400602-immunic-competitive-phase-2-data-in-multiple-sclerosis
Based on 1 analyst offering 12 month price targets for RedHill Biopharma in the last 3 months. The average price target is $12.00 with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 57.07% increase from the last price of $7.64.
https://www.tipranks.com/stocks/rdhl/forecast
Just starting to accumulate a position here as the company is one of the few doing anything with GBM or rGBM. $KZIA Kazia should not have a higher valuation IMO but I assume trials are slow to recruit due to Covid. With further positive news, Kintara could fly with its lower outstanding share count.
Seems like we have been getting some healthy accumulation of late despite the shorts endlessly trying to sell down the stock or the weird spread that keeps coming up.
We need one powerful press release to strip out this overly shorted stock and gain a positive upward momentum.
XWAVXALMIMAN
Had to add myself as I believe we will get much needed support from H.C. Wainwright & Co. plus we are well short of all analyst projecting's with the 4 buys and the twelve month price targets ranging from $12 to $26 a share.
Reassessing RedHill Biopharma
https://seekingalpha.com/article/4399389-reassessing-redhill-biopharma
Nice bump up in institutional ownership 3rd Q 2020, looking forward to Q 4 for update:
https://whalewisdom.com/stock/vtl-2
Fast money trades Friday:
https://www.cnbc.com/fast-money/
Final Trades: ADM, BITW & BFT
https://www.cnbc.com/video/2020/12/11/final-trades-adm-bitw-bft.html